Tempus AI (TEM) Revenue Outlook Boosted by Morgan Stanley Insight

Tempus AI (TEM) shares rose 30% this week after Morgan Stanley highlighted reimbursement pricing that may add between $330 million and $400 million in annual revenue from xT and xF diagnostics. CEO Eric Lefkofsky indicated that xT pricing could contribute $80 million to $100 million next year, while xF could contribute $250 million to $300 million. The company also raised its full-year revenue guidance to between $1.595 billion and $1.605 billion, reflecting approximately 25% annual growth. For investors, the revenue adjustments signify potential growth and a more favorable earnings trajectory moving forward.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.